Abstract

BackgroundRecent studies suggest a substantially reduced risk of invasive bacterial infection in children vaccinated with heptavalent pneumococcal conjugate vaccine (PCV). To investigate whether the introduction of PCV might affect clinical decision making, we conducted a cross-sectional survey aimed at Italian Pediatric physicians.ResultsThe study included 348 (46.5%) primary care pediatricians; 251 (36.4%) hospital pediatricians, and 139 (20.1%) pediatric residents. In an hypothetical scenario, a well-appearing 12-month-old child with fever without source would be sent home with no therapy by 60.7% (419/690) of physicians if the child was not vaccinated with PCV. The proportion increased to 74.2% (512/690) if the child had received PCV (P < 0.0001). Also, physicians would obtain blood tests less frequently in the vaccinated than in unvaccinated children (139/690 [20.1%] vs. 205/690 [29.7%]; P < 0.0001), and started empiric antibiotic therapy less frequently (3.0% vs. 7.5%; P < 0.0001). In the hypothetical event that white blood cell count was 17,500/μL, a significantly lower proportion of physicians would ask for erythrocyte sedimentation rate (P < 0.017), C reactive protein (P < 0.0001), blood culture (P = 0.022), and urine analysis or dipstick (P = 0.028), if the child had received PCV. Only one third of participants routinely recommended PCV.ConclusionOur data suggest that implementation of educational programs regarding the proper management of the febrile child is needed.

Highlights

  • Recent studies suggest a substantially reduced risk of invasive bacterial infection in children vaccinated with heptavalent pneumococcal conjugate vaccine (PCV)

  • Initial approach to the well-appearing young child with fever without source, with relation to his/her PCV vaccination status The proportion of participants who report to "wait-and see" was 60.7% (419/690), if the child was not vaccinated with PCV and increased to 74.2% (n = 512/690) if the child had received PCV (P < 0.0001)

  • Empiric antibiotic therapy would be started by 3.0% (21/690) of pediatricians/pediatric residents if the child had received PCV vs. 7.5% of participants (52/690) if the child was unvaccinated (P < 0.0001) (Table 1)

Read more

Summary

Introduction

Recent studies suggest a substantially reduced risk of invasive bacterial infection in children vaccinated with heptavalent pneumococcal conjugate vaccine (PCV). The management of children with a fever without a source remains controversial [1], and it is becoming even more so after the introduction of the hepta-valent pneumococcal conjugate vaccine (PCV) [1]. It has been calculated that the widespread use of PCV is associated with a decreased risk of bacterial infection from about 2–5% to less than 1% in well-appearing young children with a fever without a source [1]. Given this minimal risk, some authors hope that the management of these children will become a (page number not for citation purposes). Of concern, increasing rates of infections due to antimicrobial resistant pneumococcal serotypes not-included into the heptavalent PCV have been reported [3,4,5,6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call